Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
Tumor antigen and MHC expression in glioma cells for immunotherapeutic interventions
Christina Susanne Mullins, Carl-Friedrich Classen, Pediatrics Department, University Hospital Rostock, 18057 Rostock, Germany
Christina Susanne Mullins, Alexander Walter, Michael Linnebacher, Department of General Surgery, Molecular Oncology and Immunotherapy, University Hospital Rostock, 18057 Rostock, Germany
Michael Schmitt, Department Internal Medicine V, University Hospital Heidelberg, 69120 Heidelberg, Germany
Author contributions: Mullins CS, Walter A performed most of the experiments; Schmitt M, Classen CF, Linnebacher M planned the study, supervised and discussed the results; Mullins CS, Linnebacher M wrote and revised the manuscript; Classen CF, Schmitt M proofed the manuscript.
Correspondence to: Michael Linnebacher, PhD, Department of General Surgery, Molecular Oncology and Immunotherapy, University Hospital Rostock, Schillingallee 35, 18057 Rostock, Germany. michael.linnebacher@med.uni-rostock.de
Telephone: +49-381-4996043 Fax: +49-381-4996002
Received: August 5, 2013
Revised: October 8, 2013
Accepted: November 1, 2013
Published online: November 27, 2013
Processing time: 115 Days and 2.5 Hours
Revised: October 8, 2013
Accepted: November 1, 2013
Published online: November 27, 2013
Processing time: 115 Days and 2.5 Hours
Core Tip
Core tip: Expression of tumor-antigens and major histocompatibility complex (MHC)-machinery components was analyzed in a series of seven novel low-passage glioblastoma multiforme cell lines by flow cytometry in comparison to three commercially available standard lines. MHC class I was always expressed, MHC class II readily after interferon gamma treatment. All cell lines expressed at least two tumor antigens. No differences between newly-established and commercially available cell lines were observed. Since these novel cell lines are available in low-passages upon request, they are interesting tools for future development of immunotherapeutic strategies, associated screenings and the like.